Project Grant W81XWH1510133

This $672,394.58 project grant from the National Institutes of Health's National Institute of Dental and Craniofacial Research Oral Diseases and Disorders Research program (CFDA 93.121) supports the development of a crosslinkable tissue particle implant for regenerating craniofacial bone. Led by Leefa Biotech LLC, the one-year award aims to demonstrate improved bone regeneration in critical-size cranial bone defects using the implant compared to the current standard of care. If successful, the...

The Department of the Army Medical Command awarded a $2,756,800 Project Grant to Stanford University under the Military Medical Research and Development program (CFDA 12.420). The award will support development of an implantable device that enables personalized, sustained release of bioagents for large bone defect reconstruction and limb salvage from June 2022 through May 2026. Under the award, Stanford will establish a sheep bone transport model and test handling of a novel intramedullary...

Federal Grant Award Summary Matregenix Inc. received a $1.952 million Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded July 1, 2025, with completion scheduled for June 30, 2027. The award funds Phase II development and validation of MATRINOVA, an animal-free, amino acid-based bilayered barrier membrane designed for guided bone regeneration (GBR) in oral and craniomaxillofacial...

The Department of the Army Medical Command awarded a $2.13 million Project Grant to Palo Alto Veterans Institute For Research (doing business as Pavir) to develop a photoactivated regenerative collagen sealant for rapid vision restoration after deep corneal injuries. The period of performance for this award is from September 1, 2022 through August 31, 2025. The award is being made under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and...

Theradaptive Inc. was awarded a $3,979,465 Project Grant from the Department of the Army Medical Command on September 15, 2022 to complete the project by September 14, 2024. The grant was awarded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for battlefield medicine. Specifically, the funding will support Theradaptive's development of a sustained release...

XO Armor Technologies, Inc. was awarded $582,709 under the Military Medical Research and Development program (CFDA 12.420) by the Defense Health Agency, with an award date of September 1, 2025, and completion date of August 31, 2027. The project delivers a comparative analysis of autonomous computer-generated three-dimensional (3D) printed wrist braces versus traditional bracing methods. This research initiative aims to generate data-driven insights into the effectiveness and compliance profiles...

Federal Grant Award Summary Mobius Biotech LLC received a $305,320 Project Grant award from the National Institute of Dental and Craniofacial Research under the Oral Diseases and Disorders Research program (CFDA 93.121), effective July 7, 2025, with completion targeted for June 30, 2026. The awardee is developing and testing the Resorb3D Spreader Graft (RSG), a novel 3D-printed polycaprolactone nasal graft designed to address limitations in current nasal reconstruction approaches. The RSG...

Advanced Molecular Healix Inc. received a $296,256 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective June 1, 2025 through May 31, 2027. The grant funds research and development of a novel therapeutic strategy utilizing hypoxia-inducible factor-1 alpha (HIF-1A) messenger RNA (mRNA) to enhance pedicle flap survival in surgical wound reconstruction. The...

This federal Project Grant award from the Department of Defense's Defense Health Agency (CFDA 12.420 - Military Medical Research and Development program) provides $1,383,586.00 to Byomass Inc. to support the development of BYOM-0322, a novel biologic agent targeting the TGF-beta superfamily. The purpose is to evaluate BYOM-0322 for the prevention and treatment of breast cancer metastases and cancer cachexia (muscle wasting). This 3-year grant, awarded on February 15, 2024, will fund Byomass...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,999,336 project grant to The Trustees of the Stevens Institute of Technology on March 1, 2024. The grant will support research and development of "BIOACTIVE NERVE GRAFTS FOR PERIPHERAL NERVE REGENERATION" over a 4-year period ending February 29, 2028. As a sub-award under this project, the University of Connecticut Health Center (UCHC) will also conduct research related to this...